Pneumonia remains the most common infection-related condition that lands U.S. patients in the hospital. Identifying strategies to curb antibiotic overuse for those hospitalized with pneumonia continues to be a national priority.

Biosimilars have typically been viewed as cost-saving medications, but according to results of a study published in JAMA Health Forum, biosimilar competition did not consistently lower out-of-pocket costs for outpatients who were commercially insured. In fact, in some cases, costs even increased.

The New York State Department of Health issued an order in late March to formally implement a new law establishing access to hormonal contraception from pharmacists without a physician’s order.